Lipid-Coated Mesoporous Silica Particles for pH-Sensitive Tumor-Targeted Paclitaxel: Development, Characterization

Area of Science:

• Biomaterials Science
• Nanotechnology
• Pharmacology

Background:

• Nanoparticle drug delivery systems offer targeted delivery to tumor cells, minimizing off-target effects.
• Selective delivery enhances drug retention and reduces non-specific binding.
• Mesoporous silica nanoparticles (MSNs) are investigated for their potential as drug carriers.

Purpose of the Study:

• To construct and characterize paclitaxel (PTX)-loaded lipid-shell mesoporous silica nanoparticles (LMSNs).
• To evaluate the anti-cancer drug delivery capabilities of LMSNs.
• To assess the in vitro and in vivo performance of PTX-LMSNs.

Main Methods:

• Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) for structural analysis.
• High-performance liquid chromatography (HPLC) for drug loading (DL%) and entrapment efficiency (EE%).
• In vitro drug release studies, in vivo imaging, tissue distribution, and pharmacokinetic analysis.

Main Results:

• SEM confirmed spherical MSNs with fine pores; TEM verified uniform core-shell structures of PTX-LMSNs.
• High drug loading capacity (21.75%) and pH-dependent in vitro drug release observed.
• In vivo imaging showed prolonged retention; pharmacokinetic studies indicated significantly longer half-life compared to Taxol.

Conclusions:

• LMSNs exhibit a promising core-shell structure suitable for drug delivery.
• pH-dependent drug release favors accumulation in acidic tumor microenvironments.
• LMSNs demonstrate superior pharmacokinetic properties and prolonged in vivo retention, positioning them as a highly promising antineoplastic drug carrier system.